Table 1.
Patient characteristics
| Patient characteristic | No. of patients (n = 33) |
|---|---|
| Age | |
| Median | 56 (range 39–78) |
| Sex | |
| Male | 18 (54.5%) |
| Female | 15 (45.5%) |
| ECOG performance status | |
| 0 | 3 (9.1%) |
| 1 | 22 (66.7%) |
| 2 | 8 (24.2%) |
| Primary tumor site | |
| Major salivary gland | 9 (27.2%) |
| Parotid | 1 |
| Submandibular | 7 |
| Sublingual | 1 |
| Minor salivary gland | 17 (51.5%) |
| Floor of mouth | 2 |
| Base of tongue | 6 |
| Hard palate | 5 |
| Paranasal sinus | 2 |
| Oral tongue | 1 |
| Oral cavity | 1 |
| Other | 7 (21.2%) |
| Lacrimal gland | 1 |
| Lung | 2 |
| Breast | 2 |
| Trachea | 1 |
| Unknown primary | 1 |
| Disease distribution | |
| Locoregional disease only | 1 (3.0%) |
| Distant metastases | 32 (97.0%) |
| Lung only | 9 |
| Liver | 8 |
| Peritoneum | 2 |
| Bone | 7 |
| Skin | 1 |
| Brain | 2 |
| Leptomeninges | 1 |
| Prior therapy | |
| Systemic therapy | 19 (57.6%) |
| For recurrent/metastatic ACC | 17 |
| As adjuvant therapy (w/o RT) | 1 |
| With radiation | 7 |
| Radiation | 31 (93.9%) |
| Axitinib dose | |
| Eligible for dose escalation | 19 (57.6%) |
| Dose escalated | 15 (45.5%) |
| 7 mg b.i.d. | 6 (18.2%) |
| 10 mg b.i.d. | 9 (27.3%) |
| Dose reduced | 11 (33.3%) |
| Without prior dose escalation (n = 18) | 7 (63.6%) |
| After dose escalation (n = 15) | 4 (26.7%) |